FDA Grants Fast Track Designation to Leronlimab for Metastatic TNBC

May 7, 2019 – The FDA has granted a fast track designation to the CCR5 antagonist leronlimab (PRO140) for use in combination with carboplatin for the treatment of patients with CCR5-positive metastatic triple-negative breast cancer (TNBC). The agent, which is administered via injection, is being evaluated in clinical trial at sites that are initiating patient enrollment, such as Quest Clinical Research in San Francisco, Northwestern University Medical School … (leggi tutto)